StockNews.AI
ENSC
StockNews.AI
141 days

Ensysce Biosciences, Inc. Announces $1.1 Million Registered Direct Offering Priced At-The-Market Under Nasdaq Rules

1. Ensysce raised $1.1 million through a direct offering and private placement. 2. They issued 315,188 common shares at $3.49 per share.

2m saved
Insight
Article

FAQ

Why Bullish?

The capital raised can enhance operational flexibility and fund development, similar to past biotech capital raises that positively impacted share price.

How important is it?

The funding supports Ensysce’s development, potentially attracting investors and increasing stock demand.

Why Short Term?

The immediate influx of capital may boost investor confidence, influencing price in the near term.

Related Companies

VRTXABBVSPPI
SAN DIEGO, CA / ACCESS Newswire / March 31, 2025 / Ensysce Biosciences, Inc. (NASDAQ:ENSC) ("Ensysce" or the "Company"), a clinical-stage pharmaceutical company developing innovative solutions for severe pain relief while reducing the potential for opioid abuse and overdose, today announced that it has entered into definitive agreements, providing the Company with an aggregate gross proceeds of approximately $1.1 million, for the issuance and sale of an aggregate of 315,188 of its shares of common stock (or common stock equivalents in lieu thereof) at a purchase price of $3.49 per share (or common stock equivalent in lieu thereof) in a registered direct offering priced at-the-market under Nasdaq rules. In a concurrent private placement, the Company has also agreed to issue and sell unregistered Series A-5 warrants to purchase up to an aggregate of 315,188 shares of common stock and unregistered Series A-6 warrants to purchase up to an aggregate of 315,188 shares of common stock.

Related News